A new analysis from the peripheral arterial disease (PAD) subgroup of the large-scale COMPASS trial show that development of a major adverse limb event — the primary endpoint of the study — is ...

In my years as a patient advocate, I’ve had countless conversations with healthcare executives about the economics of limb preservation versus amputation. During one particularly candid exchange at a ...